Award
National Cancer Institute 5R21CA289167-02
Activation of Drug and Biologic Conjugates by Click Chemistry and their Tumor-selective Targeting for Prostate Cancer Suppression
Recipient
University of Texas Health Science Center, San Antonio, TX
Award Amount
$178,819.00
Ceiling
$178,819.00
Awarded
March 03, 2025
Identifier
5R21CA289167-02
This award funds research on a novel targeted drug activation method using click chemistry to treat castration-resistant prostate cancer, aiming to improve treatment specificity and reduce toxicity.
Description
A project to explore a novel anti-cancer approach against castration-resistant prostate cancer (CRPC) that activates a pro-drug conjugate specifically in tumor tissue to ablate cancer cells without off-target toxicity. The approach uses bioorthogonal click chemistry to release drugs selectively in cancer cells, focusing on small-molecule anti-cancer agents and chemotherapy drugs for CRPC. The project involves synthesis, in vitro and in vivo testing, and aims for high clinical translation potential.